RNXT
RenovoRx, Inc.
Biotechnology
Market Cap$32M
5Y Perf.-91.4%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
RNXT vs CASI
Revenue, margins, valuation, and 5-year total return — side by side.
CASI
CASI Pharmaceuticals, Inc.
Biotechnology
Market Cap$2M
5Y Perf.-98.6%
RNXT vs CASI — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | RNXT | CASI |
|---|---|---|
| Industry | Biotechnology | Biotechnology |
| Market Cap | $32M | $2M |
| Revenue (TTM) | $928K | $27M |
| Net Income (TTM) | $-11M | $-49M |
| Gross Margin | 67.8% | 35.8% |
| Operating Margin | -12.5% | -168.0% |
| Total Debt | $278K | $22M |
| Cash & Equiv. | $7M | $13M |
RNXT vs CASI — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
RNXT
CASI
| Stock | Aug 21 | May 26 | Return |
|---|---|---|---|
| RenovoRx, Inc. (RNXT) | 100 | 8.6 | -91.4% |
| CASI Pharmaceutical… (CASI) | 100 | 1.4 | -98.6% |
Price return only. Dividends and distributions are not included.
Quick Verdict: RNXT vs CASI
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: RNXT leads in 4 of 6 categories, making it the strongest pick for growth and revenue expansion and capital preservation and lower volatility. CASI Pharmaceuticals, Inc. is the stronger pick specifically for profitability and margin quality and dividend income and shareholder returns. As sector peers, any of these can serve as alternatives in the same allocation.
RNXT
RenovoRx, Inc.
The Growth Play
RNXT carries the broadest edge in this set and is the clearest fit for growth exposure and long-term compounding.
- EPS growth 26.0%
- -87.9% 10Y total return vs CASI's -99.0%
- Lower volatility, beta 1.18, Low D/E 6.2%, current ratio 4.10x
Best for: growth exposure and long-term compounding
CASI
CASI Pharmaceuticals, Inc.
The Quality Compounder
CASI is the clearest fit if your priority is quality and dividends.
- -183.9% margin vs RNXT's -12.0%
- 31.1% yield; the other pay no meaningful dividend
Best for: quality and dividends
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | RNXT | 46.2% revenue growth vs CASI's -15.8% |
| Quality / Margins | CASI | -183.9% margin vs RNXT's -12.0% |
| Stability / Safety | RNXT | Lower D/E ratio (6.2% vs 12.0%) |
| Dividends | CASI | 31.1% yield; the other pay no meaningful dividend |
| Momentum (1Y) | RNXT | -17.0% vs CASI's -91.2% |
| Efficiency (ROA) | RNXT | -99.1% ROA vs CASI's -131.5% |
RNXT vs CASI — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
FY 2024
FY 2019
RNXT vs CASI — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLRNXTLAGGINGCASI
CASICASI Pharmaceuticals,…
2leads
RNXTRenovoRx, Inc.
2leads
6 Total Categories
CATEGORYLEADERvs CASIMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
CASI3/5
Valuation MetricsMultiples, price ratios, and targets
CASI2/3
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
RNXT6/7
Total Returns1Y, 3Y, 5Y total returns with dividends
RNXT6/6
Risk & VolatilityBeta, volatility, and downside exposure
Tied
—
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
CASI leads this category, winning 3 of 5 comparable metrics.
Income & Cash Flow (Last 12 Months)
CASI is the larger business by revenue, generating $27M annually — 28.9x RNXT's $928,000. Profitability is closely matched — net margins range from -183.9% (CASI) to -12.0% (RNXT).
| Metric | RNXTRenovoRx, Inc. | CASICASI Pharmaceutic… |
|---|---|---|
| RevenueTrailing 12 months | $928,000 | $27M |
| EBITDAEarnings before interest/tax | -$9M | -$44M |
| Net IncomeAfter-tax profit | -$11M | -$49M |
| Free Cash FlowCash after capex | -$10M | $0 |
| Gross MarginGross profit ÷ Revenue | +67.8% | +35.8% |
| Operating MarginEBIT ÷ Revenue | -12.5% | -168.0% |
| Net MarginNet income ÷ Revenue | -12.0% | -183.9% |
| FCF MarginFCF ÷ Revenue | -11.2% | -103.2% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | -60.5% |
| EPS Growth (YoY)Latest quarter vs prior year | +19.3% | -23.6% |
CASI leads this category, winning 3 of 5 comparable metrics.
Valuation Metrics
CASI leads this category, winning 2 of 3 comparable metrics.
Valuation Metrics
| Metric | RNXTRenovoRx, Inc. | CASICASI Pharmaceutic… |
|---|---|---|
| Market CapShares × price | $32M | $2M |
| Enterprise ValueMkt cap + debt − cash | $25M | $11M |
| Trailing P/EPrice ÷ TTM EPS | -2.38x | -0.06x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 750.13x | 0.08x |
| Price / BookPrice ÷ Book value/share | 4.64x | 1.25x |
| Price / FCFMarket cap ÷ FCF | — | — |
CASI leads this category, winning 2 of 3 comparable metrics.
Profitability & Efficiency
RNXT leads this category, winning 6 of 7 comparable metrics.
Profitability & Efficiency
RNXT delivers a -137.5% return on equity — every $100 of shareholder capital generates $-137 in annual profit, vs $-3 for CASI. RNXT carries lower financial leverage with a 0.06x debt-to-equity ratio, signaling a more conservative balance sheet compared to CASI's 11.96x. On the Piotroski fundamental quality scale (0–9), RNXT scores 5/9 vs CASI's 2/9, reflecting solid financial health.
| Metric | RNXTRenovoRx, Inc. | CASICASI Pharmaceutic… |
|---|---|---|
| ROE (TTM)Return on equity | -137.5% | -3.0% |
| ROA (TTM)Return on assets | -99.1% | -131.5% |
| ROICReturn on invested capital | — | -153.0% |
| ROCEReturn on capital employed | -3.4% | -104.6% |
| Piotroski ScoreFundamental quality 0–9 | 5 | 2 |
| Debt / EquityFinancial leverage | 0.06x | 11.96x |
| Net DebtTotal debt minus cash | -$7M | $9M |
| Cash & Equiv.Liquid assets | $7M | $13M |
| Total DebtShort + long-term debt | $278,000 | $22M |
| Interest CoverageEBIT ÷ Interest expense | — | -66.88x |
RNXT leads this category, winning 6 of 7 comparable metrics.
Total Returns (Dividends Reinvested)
RNXT leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in RNXT five years ago would be worth $1,212 today (with dividends reinvested), compared to $94 for CASI. Over the past 12 months, RNXT leads with a -17.0% total return vs CASI's -91.2%. The 3-year compound annual growth rate (CAGR) favors RNXT at -31.8% vs CASI's -60.8% — a key indicator of consistent wealth creation.
| Metric | RNXTRenovoRx, Inc. | CASICASI Pharmaceutic… |
|---|---|---|
| YTD ReturnYear-to-date | +5.4% | -81.6% |
| 1-Year ReturnPast 12 months | -17.0% | -91.2% |
| 3-Year ReturnCumulative with dividends | -68.2% | -94.0% |
| 5-Year ReturnCumulative with dividends | -87.9% | -99.1% |
| 10-Year ReturnCumulative with dividends | -87.9% | -99.0% |
| CAGR (3Y)Annualised 3-year return | -31.8% | -60.8% |
RNXT leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
Evenly matched — RNXT and CASI each lead in 1 of 2 comparable metrics.
Risk & Volatility
CASI is the less volatile stock with a -0.12 beta — it tends to amplify market swings less than RNXT's 1.18 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. RNXT currently trades 60.7% from its 52-week high vs CASI's 4.9% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | RNXTRenovoRx, Inc. | CASICASI Pharmaceutic… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.17x | -0.22x |
| 52-Week HighHighest price in past year | $1.45 | $3.09 |
| 52-Week LowLowest price in past year | $0.70 | $0.05 |
| % of 52W HighCurrent price vs 52-week peak | +60.7% | +4.9% |
| RSI (14)Momentum oscillator 0–100 | 45.0 | 24.2 |
| Avg Volume (50D)Average daily shares traded | 379K | 146K |
Evenly matched — RNXT and CASI each lead in 1 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
CASI is the only dividend payer here at 31.10% yield — a key consideration for income-focused portfolios.
| Metric | RNXTRenovoRx, Inc. | CASICASI Pharmaceutic… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | +31.1% |
| Dividend StreakConsecutive years of raises | — | 0 |
| Dividend / ShareAnnual DPS | — | $0.05 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
CASI leads in 2 of 6 categories (Income & Cash Flow, Valuation Metrics). RNXT leads in 2 (Profitability & Efficiency, Total Returns). 1 tied.
Best OverallRenovoRx, Inc. (RNXT)Leads 2 of 6 categories
Loading custom metrics...
RNXT vs CASI: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Which is the better long-term investment — RNXT or CASI?
Over the past 5 years, RenovoRx, Inc.
(RNXT) delivered a total return of -87. 9%, compared to -99. 1% for CASI Pharmaceuticals, Inc. (CASI). Over 10 years, the gap is even starker: RNXT returned -88. 1% versus CASI's -99. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — RNXT or CASI?
By beta (market sensitivity over 5 years), CASI Pharmaceuticals, Inc.
(CASI) is the lower-risk stock at -0. 22β versus RenovoRx, Inc. 's 1. 17β — meaning RNXT is approximately -625% more volatile than CASI relative to the S&P 500. On balance sheet safety, RenovoRx, Inc. (RNXT) carries a lower debt/equity ratio of 6% versus 12% for CASI Pharmaceuticals, Inc. — giving it more financial flexibility in a downturn.
03Which is growing faster — RNXT or CASI?
On earnings-per-share growth, the picture is similar: RenovoRx, Inc.
grew EPS 26. 0% year-over-year, compared to -26. 7% for CASI Pharmaceuticals, Inc.. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
04Which has better profit margins — RNXT or CASI?
CASI Pharmaceuticals, Inc.
(CASI) is the more profitable company, earning -137. 6% net margin versus -205. 0% for RenovoRx, Inc. — meaning it keeps -137. 6% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: CASI leads at -138. 8% versus -255. 1% for RNXT. At the gross margin level — before operating expenses — RNXT leads at 100. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — RNXT or CASI?
In this comparison, CASI (31.
1% yield) pays a dividend. RNXT does not pay a meaningful dividend and should not be held primarily for income.
06Is RNXT or CASI better for a retirement portfolio?
For long-horizon retirement investors, CASI Pharmaceuticals, Inc.
(CASI) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0. 22), 31. 1% yield). Both have compounded well over 10 years (CASI: -99. 0%, RNXT: -88. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between RNXT and CASI?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
In terms of investment character: RNXT is a small-cap quality compounder stock; CASI is a small-cap income-oriented stock. CASI pays a dividend while RNXT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.